Haemonetics Q2 revenue falls 5.3% to $327.3 million; raises FY2026 EPS guidance
Haemonetics reported second-quarter fiscal 2026 revenue of $327.3 million, down 5.3% from a year earlier, while GAAP net income rose 14.3% and adjusted earnings per diluted share rose 13.4% to $1.27. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.80 to $5.00 and its free cash flow guidance to $170 million to $210 million, and reaffirmed its adjusted operating margin guidance of 26% to 27%.
Key points
- Q2 revenue was $327.3 million, down 5.3%; organic ex-CSL revenue grew 9.4%.
- GAAP earnings per diluted share were $0.81, up from $0.66; adjusted earnings per diluted share were $1.27.
- Fiscal 2026 adjusted EPS guidance raised to $4.80 to $5.00 from $4.70 to $5.00; free cash flow guidance raised to $170 million to $210 million from $160 million to $200 million.
- Q2 operating expenses included $8.6 million of intangible asset impairment charges.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.